^
Association details:
| Biomarker: | CLDN18.2 positive |
|---|---|
| Cancer: | Gastric Adenocarcinoma |
| Drug: | Vyloy (zolbetuximab-clzb) (CLDN18.2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ILUSTRO: Phase 2 Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Published date:
10/02/2023
Excerpt:
Zolbetuximab plus mFOLFOX6 demonstrated promising efficacy in previously untreated patients with CLDN18.2-positive G/GEJ adenocarcinoma. These data support the first-line development of zolbetuximab in patients whose tumors are CLDN18.2 positive. Across cohorts, zolbetuximab treatment was tolerable with no new safety signals.
Secondary therapy:
Modified FOLFOX6
DOI:
10.1158/1078-0432.CCR-23-0204
